BioLineRx Ltd - Company Profile
Powered by 
All the sales intelligence you need on BioLineRx Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioLineRx Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioLineRx Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioLineRx Ltd (BioLineRx) is a biopharmaceutical company focused on developing therapies in oncology and rare diseases. The company's main activities include the development and commercialization of innovative therapeutic solutions. Its major products include APHEXDA (Motixafortide), a peptide for stem cell mobilization and solid tumor treatment, and GLIX1, a small molecule targeting DNA damage response in cancers. BioLineRx collaborates with Ayrmid Pharma Ltd. and Gloria for the development and commercialization of its products. The company's products are primarily used by healthcare providers for treating patients with unmet medical needs in oncology. BioLineRx has established partnerships for distribution in the US and Asia. The company is headquartered in Modi'in, Israel.
Headquarters
Israel
Address
Modi’in Technology Park, 2 HaMa’ayan Street, Modi'in-Maccabim-Re'ut, 7177871
Website
www.biolinerx.com
Telephone
972 8 6429100
No of Employees
24
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BLRX (TLV)
Revenue (2024)
$1.2M
-95.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
78%
(2024 vs 2023)
Market Cap*
$13.1M
Net Profit Margin (2024)
XYZ
-438.9%
(2024 vs 2023)
* As of and is in US$
BioLineRx Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Aphexda (Motixafortide): Multiple Myeloma, Sickle Cell Disease and Pancreatic Cancer |
| BL-5010: Skin Lesions |
| GLIX1: DNA damage response |
Competitor Comparison
| Key Parameters | BioLineRx Ltd | X4 Pharmaceuticals Inc | Aclaris Therapeutics Inc | Genzyme Corp | Spexis AG |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | United States of America | Switzerland |
| City | Modi'in-Maccabim-Re'ut | Boston | Wayne | Cambridge | Allschwil |
| State/Province | - | Massachusetts | Pennsylvania | Massachusetts | - |
| No. of Employees | 24 | 45 | 69 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Aharon Schwartz | Chairman | Executive Board | 2004 | 83 |
| Philip A. Serlin | Chief Executive Officer | Senior Management | 2016 | 65 |
| Mali Zeevi | Chief Financial Officer | Senior Management | 2016 | 50 |
| Ella Sorani | Chief Development Officer | Senior Management | 2021 | 58 |
| Bela Neiman | Vice President - Analytical Chemistry | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer